Bio-pharmaceutical company ANI Pharmaceuticals Inc (ANI) (Nasdaq: ANIP) revealed on Monday that the Abbreviated New Drug Application (ANDA) for Fluoxetine Oral Solution, USP 20mg/5mL has received U.S. Food and Drug Administration (FDA) approval,
The company said that Fluoxetine Oral Solution is the generic version of the Reference Listed Drug (RLD) Prozac.
According to healthcare data and analytics provider IQVIA/IMS Health, the current annual US market for Fluoxetine Oral Solution is approximately USD14.6m, ANI stated.
ANI develops, manufactures and markets high quality branded and generic prescription pharmaceutical products, including for diseases with high unmet medical needs.
Accord Healthcare launches Lurasidone HCL tablets
US FDA Accepts the ATI-1501 NDA, According to Appili Therapeutics
Sanofi reports Q4 sales of Dupixent up 42%
Upsher-Smith Laboratories launches Fluoxetine Oral Solution, USP, 20mg/5mL
Astellas Pharma enters into Asset Purchase Agreement with Sandoz
ANI Pharmaceuticals Launches Levocarnitine Tablets USP Following US FDA Approval
Hartness Named to Bryn Pharma Board of Directors
Accord Healthcare adds Bendamustine Lyo. Injection to range of chemotherapy drugs
ANI Pharmaceuticals Receives FDA Approval, Launches Fluoxetine Oral Solution USP
ANI Pharmaceuticals receives FDA approval for Fluoxetine Oral Solution USP
Prasco Laboratories introduces Authorised Generic of ZIOPTAN in partnership with Thea Pharma
ANI Pharmaceuticals declares FDA approval and commercialisation of Trimethoprim Tablets USP
McKinley, Boothe Named to Maxwell Biosciences Board of Directors